Who founded Ocugenix?

Ocugenix was founded by Sean McDonald in 2015.

How much funding has Ocugenix raised?

Ocugenix has disclosed $1.6M raised across 2 rounds.

Where is Ocugenix headquartered?

Ocugenix is headquartered in Pittsburgh, US.

Ocugenix

Pittsburgh, US · Founded 2015 · Delaware corporation

Find your way into Ocugenix

Paths you didn't know you had: your email and LinkedIn already hold routes to the Ocugenix team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.

Biotech Healthtech Medical Devices

Founders & leadership

Ocugenix was founded in 2015 by Sean McDonald.

Sean McDonaldFounder · President & CEOSean McDonald is Chief Executive Officer and co-founder of Ocugenix, a biotechnology company developing therapeutics for eye diseases including glaucoma and wet macular degeneration. He previously served as President and CEO of Precision Therapeutics, where he built a personalized medicine company, and held leadership roles at McKesson and as founder of Automated Healthcare, a robotics-based pharmacy automation company.

Alan WellsChief Scientific Officer

Richard S. KollenderNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$1.6M disclosed across 2 rounds · 2019–2021

▶$1.3MraisedSep 2021 · 8 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Richard S. KollenderDirector
Sean McDonaldExecutive Officer, Director
Paul USA ChaneyDirector
Thomas C. HohmanDirector

Offering amount: $4M
Amount sold: $1.3M
First sale: Jul 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$350KraisedOct 2019 · 6 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Sean McDonaldExecutive Officer, Director
Richard S. KollenderDirector

Offering amount: $350K
Amount sold: $350K
First sale: Aug 2019
Incorporated: Corporation, Delaware, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Ocular TherapeutixOcular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.

OphthalmologytimesOphthalmology Times is a medical news publication covering clinical research, drug approvals, and treatment developments in eye care for ophthalmologists and other eye care professionals. It publishes articles, videos, podcasts, a digital edition, and continuing medical education content.

OisOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Ocugenix.

Frequently asked questions

What does Ocugenix do?: Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.
Who founded Ocugenix?: Ocugenix was founded by Sean McDonald in 2015.
How much funding has Ocugenix raised?: Ocugenix has disclosed $1.6M raised across 2 rounds.
Where is Ocugenix headquartered?: Ocugenix is headquartered in Pittsburgh, US.